Annexon, INC Schedule 13G passive stakes

State Street Corporation has disclosed beneficial ownership of 6% of Annvon Inc.'s common stock as of June 30, 2026.

Redmile Group, LLC, along with Jeremy C. Green and RedCo II Offshore SPV LLC, has reported beneficial ownership of 9.9% of Annexon, Inc.'s common stock as of July 8, 2026.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 11.9% of Annexon Inc.'s common stock as of June 30, 2026.

Biotechnology Value Fund and its affiliates have disclosed a 5.4% beneficial ownership stake in Annexon, Inc. following the exercise of pre-funded warrants.

The Vanguard Group has amended its Schedule 13G for Annexon Inc., reporting 0% beneficial ownership following an internal realignment.

FMR LLC and Abigail P. Johnson have disclosed a 7.1% beneficial ownership stake in Annexon Inc. common stock as of December 31, 2025.

BlackRock, Inc. has reported an increased beneficial ownership of 6.1% in Annexon Inc.'s common stock as of December 31, 2025.

FMR LLC and Abigail P. Johnson have disclosed a 10.1% beneficial ownership stake in Annexon Inc., holding over 11 million shares of common stock.

The Vanguard Group has reported a passive beneficial ownership of 5.31% in Annexon Inc., totaling 5,835,112 common shares.

Logos Global Management LP and its affiliates have filed an amended Schedule 13G, reporting zero beneficial ownership in Annexon, Inc. common stock.

FMR LLC and Abigail P. Johnson report a 14.3% beneficial ownership stake in Annexon Inc. common stock as of June 30, 2025.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has disclosed a beneficial ownership of 0.1% in Annexon, Inc., totaling 95,430 shares, as of March 31, 2025.

The Vanguard Group has filed an amended Schedule 13G, disclosing a reduction in its beneficial ownership of Annexon Inc. common stock to 4.9% as of March 31, 2025.

Logos Global Management LP and its affiliated entities have disclosed a passive beneficial ownership of 6.0% in Annexon, Inc.'s common stock, totaling 6,600,000 shares.

Bain Capital Life Sciences Entities have filed an amendment to their Schedule 13G, disclosing a beneficial ownership of 4.9% in Annexon, Inc. as of December 31, 2024, indicating a reduction below the 5% reporting threshold.

The Vanguard Group has filed a Schedule 13G, disclosing a 5.2% passive beneficial ownership stake in Annexon Inc. as of December 31, 2024.